Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCO-101 + FOLFIRI
- Development stage
- Unknown
- Lead developer
- Scandion Oncology
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SCO-101 + FOLFIRI is an investigational drug combination comprised of SCO-101, a small molecule inhibitor of ABCG2, UGT1A1, and SRPK1, administered together with the FOLFIRI chemotherapy regimen (folinic acid [leucovorin], fluorouracil [5-FU], irinotecan) for treatment of metastatic colorectal cancer (mCRC). SCO-101 modulates resistance mechanisms and increases exposure of irinotecan's active metabolite SN-38, potentially improving efficacy in patients who have progressed on standard therapies. In multiple parts of the CORIST phase II trial, SCO-101 was given orally for several days (typically days 1–6) and FOLFIRI intravenously (days 5–7) in recurring two-week cycles. This combination has shown promising activity, increasing progression-free survival in a drug-resistant mCRC population and maintaining a favorable safety profile[1][3][5].
- Other names
- SCO-101 plus FOLFIRISCO101 plus FOLFIRISCO 101 plus FOLFIRISCO-101 combined with FOLFIRISCO101 combined with FOLFIRISCO 101 combined with FOLFIRISCO-101 + leucovorin + fluorouracil + irinotecan
02
Targets
UGT1A1 (UDP-glucuronosyltransferase 1A1)SRPK1 (Serine/arginine-rich protein-specific kinase 1)ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on SCO-101 + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCO-101 + FOLFIRI.